Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- US FDA Accepts Xofluza’s Granule Version, Pediatric Use for Review: Shionogi
March 30, 2020
- Kissei Licenses CG Oncology's Oncolytic Viral Therapy in Asia Excluding China
March 30, 2020
- Osaka Tax Bureau Challenges Ruling on Shionogi Case
March 27, 2020
- JCR Acquiring ArmaGen to Expedite Drug Development for Lysosomal Diseases
March 27, 2020
- Eisai Files CTCL/PTCL Drug at MHLW Request
March 27, 2020
- Yoshindo Curbs Shipments of Tranexamic Acid as Coronavirus Hits API Supplies
March 27, 2020
- Ono, BMS Submit Opdivo/Yervoy Duo for NSCLC in Combination with Chemo
March 27, 2020
- Takeda to Introduce Fronteo’s Drug Discovery Support AI System
March 27, 2020
- Roche Diagnostics Files New Coronavirus Test in Japan
March 27, 2020
- Pfizer Japan Extends Voluntary Ban on Doctor Visits to April 10
March 27, 2020
- Otsuka’s PDE4 Inhibitor Difamilast Delivers Positive Data for Atopic Dermatitis in Japan PIII
March 27, 2020
- COVID-19-Disrupted Air Freight Hitting Commodity Transports, but No Major Impact So Far on Drugs
March 26, 2020
- Fujifilm Launches Contract Services for Process Development, Manufacturing of Liposome Formulations
March 26, 2020
- Asahi Kasei’s US Subsidiary Turbocharges Ventilator Production amid Coronavirus Outbreak
March 26, 2020
- Face Mask Shortages Crippling Drug Makers’ Business Activities, Travel Restrictions Could Delay Approval
March 26, 2020
- Aspen Japan President to Lead Sandoz K.K.
March 26, 2020
- Boehringer Ingelheim Recalling Alesion after Impurities Detected
March 25, 2020
- Astellas Inks Biotech R&D Pact for Next-Gen I/O Therapy
March 25, 2020
- AnGes Now Ready to Launch Preclinical Study for Coronavirus DNA Vaccine
March 25, 2020
- Nippon Chemiphar Snaps Up Japan Rights for Tumor Microenvironment Therapy from Delta-Fly
March 25, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…